Goldfinch Bio Announces Collaborations with Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to Augment World’s Largest Genomic Registry of Patients with Kidney Disease
Cambridge, Mass., October 17, 2017 – Goldfinch Bio, a company singularly focused on discovering and developing precision therapies to treat patients with kidney disease, today announced collaborations with the Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to generate genomic data on over 1,500 patients with proteinuric kidney disease. The collaborations will integrate genomic analysis and de-identified clinical data from Mount Sinai’s BioMe BioBank and Vanderbilt’s BioVU BioBank to expand Goldfinch’s Patient Registry, generating an unparalleled collection of insights from patients with kidney disease.
Goldfinch Bio is leading a new age of therapeutic discovery and development in the kidney space, and is building the world’s largest genomic registry of patients with kidney disease to inform new disease targets, pathways, and biomarkers for the discovery and development of novel therapies. The patient registry is a key component of the company’s integrated product engine, which will drive breakthroughs in genetics and biology to bring precision medicines to patients with kidney disease.
In October 2017, Goldfinch announced the Company’s foundational patient registry collaboration with The Nephrotic Syndrome Study Network (NEPTUNE), a network of academic centers focused on clinical and translational research on kidney diseases presenting as Nephrotic Syndrome. The collaborations with Mount Sinai and Vanderbilt University Medical Center build upon this foundation, creating a comprehensive, federated database that integrates patient clinical data with molecular characterization at the DNA, RNA, and protein level.
“We are thrilled to work with the Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to advance our understanding of the molecular pathways of kidney disease and bring precision medicines to patients,” stated Abbie Celniker, Ph.D., interim chief executive officer of Goldfinch.
About Goldfinch Bio
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.
Goldfinch Bio Contact
Cook Williams Communications, Inc.